zoledronic acid has been researched along with Muscle Weakness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chia, FL; Ho, BC; Lim, JH; Lim, TC; Thirugnanam, U; Thong, BY | 1 |
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
2 other study(ies) available for zoledronic acid and Muscle Weakness
| Article | Year |
|---|---|
A 62-year-old man with progressive weakness, multiple neurologic deficits, and hypernatremia.
Topics: Calcium; Comorbidity; Diagnosis, Differential; Diphosphonates; Drug Therapy, Combination; Humans; Hypernatremia; Imidazoles; Male; Middle Aged; Muscle Weakness; Nervous System Diseases; Pituitary Diseases; Primary Dysautonomias; Sjogren's Syndrome; Vitamin D; Zoledronic Acid | 2014 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |